Table 3.
MRC-ECOG UKALLXII/EC2993: outcomes by risk classification
| Patient Group | # of Patients | 5-Yr Overall Survival (%) | 5-Yr Relapse Rate (%) | 5-Yr Non-relapse Mortality (%) |
|---|---|---|---|---|
| Standard Risk | 512 | |||
|
| ||||
| Sibling Donor | 218 | 62 | 24 | 20 |
| No Donor | 294 | 52 | 49 | 7 |
|
| ||||
| High Risk | 401 | |||
|
| ||||
| Sibling Donor | 171 | 41 | 37 | 36 |
| No Donor | 230 | 35 | 63 | 14 |
|
| ||||
| Ph+ Very High Risk | 267 | |||
|
| ||||
| Sibling Allo HCT | 45 | 44 | 43 | 27 |
| MUD Allo HCT | 31 | 36 | 34 | 47 |
| Chemotherapy | 82 | 19 | 90 | 17 |
*
High-risk is defined as age ≥35 years, WBC > 30,000/μL for patients with B-cell disease or WBC > 100,000/μL for patients with T-cell disease, or time to attain CR > 4 weeks.